Siga Technologies Inc.

Kineta Four, LLC

Siga Pharmaceuticals, Inc.

Other

Kineta, Inc.

Kineta Viral Hemorrhagic Fever, LLC

Dennis E Hruby

Dongcheng Dai

Tove C Bolken

Sean M Amberg

Shanthakumar R Tyavanagimatt

William C Weimers

Melialani A C L S Anderson

N K Peter Samuel

Michael H O'Neill

Ying Tan

Kelley A McCloughan

Gary Sweetapple

Dylan Nelson

Tove′ C Bolken

Chelsea M Byrd

Thomas R Bailey

Robert Jordan

Gopi Krishna Kasi

James R Burgeson

Ryan A Larson

Robert D Allen, Iii

Joseph Paz

N K Samuel

Matthew Reeves

Christine A Franke

Kris Holt

Melialani A C L Stone

Tové C Bolken

Tove' C Bolken

Melialani Acls Anderson

Steven Priebe

Vincent A Fischetti

Christopher S Liu

Scott J Hultgren

Peter N K Samuel

Hal C Jones

Amy K Evans

Stephen Whitehead

Aldis Darzins

Travis K Warren

Michael H O'NEILL

Melialani ACL Stone

Peter NK Samuel

Shantakumar R Tyavanagimatt

Melialani Acl Stone

Michael H O'neill

Kelley A Mccloughan

Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindo1-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Polymorphic forms of ST-246 and methods of preparation

Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

The present invention is directed to a dry suspension for reconstitution containing Tecovirimat (ST-246) powder and simethicone. The dry suspension is dispersed in water to provide an aqueous pharmaceutical suspension formulation for oral administration for treating orthopoxvirus infections and/or eczema vaccinatum. The suspension formulation exhibits excellent stability and good dissolution and has an improved taste and texture.

ST-246 (tecovirimat monohydrate) suspension formulations

The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation.

ST-246 liquid formulations and methods

Disclosed are methods for hydration of ST-246 particles comprising exposing said particles to moisture by conveying volumes of air containing moisture.

Rehydration of micronized tecovirimat monohydrate

Rehydration of micronized tecovirmimat monohydrate

Disclosed are methods for the preparation of amorphous N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-benzamide for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus. Also disclosed are methods for the preparation of amorphous solid dispersion of N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-benzamide.

Amorphous Tecovirimat preparation

Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by the Arenavirus family such as Lassa fever, Argentine hemorrhagic fever, Bolivian hemorrhagic fever, and Venezuelan hemorrhagic fever.

Antiviral drugs for treatment of arenavirus infection

Compounds, pharmaceutical compositions and methods for treating viral and bacterial infections, by administering certain thiourea compounds, specifically acylthiourea, carboximidoylthiourea and S-alkyl isothiourea derivatives and analogs, in therapeutically effective amounts are disclosed.

Inhibitors and methods of inhibiting bacterial and viral pathogens

Growing community of inventors

Albany, OR, United States of America

Dennis E Hruby